Our focus is finding therapeutic solutions for patients with unmet medical needs. By developing cellular disease models directly from patient cells we develop therapeutic molecules up to the preclinical proof of concept, covering aHIGHLY INNOVATIVE PATIENT BASED THERAPY DEVELOPMENT
“from bed to bench and back to bed”
We are at a transformational time in biomedical research. Disruptive technologies have made human disease models a reality. Patient-derived material lies at the heart of this effort, which we at Ksilink access through our clinical programs. The models we are creating recapitulate the actual disease mechanisms in patients. Drug development, has been vertically accelerated as a result. Costs are lessened and chances of success bolstered. During this paradigm shift access to patient material and modeling know how is becoming a competitive game changer. Ksilink is designed to be at the forefront of this new development.
Ksilink is working on diseases with a high medical need. By applying break-through technologies and know how we are combining medical needs with market expectations and technical feasability.
The complexity of patient based models is transforming entrenched work patterns between public research and industry. Access to patient derived, disease-relevant models and the most adequate competences for analyzing phenotypic screening results is becoming a competitive game changer. From an industry perspective, it is critical who will first access the relevant models – and further to that, who is able to best implement these models into the drug discovery process. Beside our in house expertise, Ksilink has access to a constantly growing network of leading clinicians and academics in France and Germany. Once the right partners are identified, Ksilink drives its collaborative drug discovery projects in a highly industrialized and standardized surrounding. Ksilink thus offers a critical advantage to its clients– with its established expertise it can generate validated patient based models within a short time.
Derisking Drug Discovery
We view disease modeling as a competitive game changer in future drug development. iPSCs combined with the latest gene editing technologies can build highly relevant disease models that directly reflect human disease at a patient-specific level. The use of such models is likely to positively impact attrition during Phase II efficacy studies. Our strategy for competitiveness, therefore, expands well beyond libraries and Medchem. Combined with our high-end target free discovery platform and medicinal chemistry capacities, our approach is worldwide unique.
An integrated bed to bench to bed effort goes far beyond the capacities of a single player. It requires a concerted effort by many sectors of the biomedical enterprise in France and Germany. Ksilink can count on founding partners across a wide spectrum from both the private and public sectors. Together, Ksilink and its founding partners span the full range of development competences and effectively link patient needs to scientific excellence.
